Daxor Unveils Faster Blood Volume Analyzer at HFSA 2026

Event summary

Daxor will showcase its FDA-cleared next-gen Blood Volume Analyzer (BVA) at HFSA 2026, offering 3x faster results with 50% less blood.
Two independent clinical ePosters will present data on BVA's use in complex heart failure, LVAD, and total artificial heart patients.
The event runs October 9–12, 2026, in Phoenix, AZ, with Daxor participating in Device Day and exhibiting at Booth #803.
Daxor's next-gen BVA is lab-based, battery-operated, and delivers >95% measurement accuracy.

The big picture

Daxor's next-gen BVA addresses a critical gap in heart failure management, where clinicians have historically relied on indirect methods. The technology's speed and precision could reduce hospital stays and readmissions, aligning with value-based healthcare trends. The HFSA 2026 showcase positions Daxor to capture a larger share of the growing market for advanced diagnostic tools in cardiology.

What we're watching

Clinical Adoption: How the 3x faster workflow and 50% reduced blood sample size will accelerate BVA adoption in hospitals and clinics.
Market Expansion: Whether Daxor can leverage HFSA 2026 to expand its reach in the multi-billion-dollar heart failure management market.
Competitive Positioning: The pace at which competitors may respond to Daxor's next-gen BVA advancements in diagnostic precision.